查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1992527

血液管路套裝市場：按類型、材料、最終用戶和應用分類－2026-2032年全球市場預測

Blood Tubing Set Market by Type, Material, End-User, Usage - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年血液輸液管路套裝市值為10.4億美元，預計2026年將成長至11.2億美元，複合年成長率為7.31%，到2032年將達到17.1億美元。

主要市場統計數據
基準年 2025 10.4億美元
預計年份：2026年 11.2億美元
預測年份 2032 17.1億美元
複合年成長率 (%) 7.31%

這是一部重點突出、注重實踐的介紹性文章，說明了影響現代血液管路套裝策略的臨床、材料、監管和商業性趨勢。

本執行摘要概述了血液輸液管路組件的現狀，這是一個複雜且快速發展的領域，並闡述了影響採購和臨床實踐的技術、監管和商業性因素。血液輸液管路組件融合了醫療設備設計、生物相容性材料科學以及嚴格的滅菌和安全通訊協定，所有這些因素共同決定了其臨床適用性和採購偏好。該行業服務於多種臨床路徑，包括血漿置換、血液透析和輸血，每種路徑對管路組件的配置、耐用性和與輔助設備的兼容性都有獨特的要求。

本報告探討了正在重新定義整個產業的產品設計、安全和供應鏈整合的技術、監管和營運轉折點。

受技術、監管和營運等多方面因素的影響，血液管材市場格局正經歷變革性變化。材料和擠出製程的創新使得管材能夠更纖細、更柔韌、更易萃取，從而降低不利事件風險，並方便臨床醫生操作。同時，滅菌方法和包裝的創新在降低污染風險的同時，也滿足了分散式醫療環境中長期儲存的需求。

對近期關稅調整如何影響關鍵消耗品的採購選擇、製造地策略和供應商多元化進行全面分析。

近期關稅措施為依賴進口醫療耗材的機構的採購、成本管理和供應鏈策略帶來了新的變數。關稅調整可能導致不同採購區域之間成本出現顯著差異，並促使企業重新評估長期供應商關係。採購團隊可以採取措施來減輕關稅結構變化的影響，例如供應商多元化、增加本地庫存緩衝或加快替代供應商的認證流程。

從洞察市場、細分的主導出發，解釋了類型、材料、最終用戶環境、銷售管道以及一次性產品和可重複使用產品之間的觀點動態如何對採購和設計選擇產生重大影響。

細分市場分析揭示了每種類型、材料、終端用戶環境、銷售管道和使用模式的不同促進因素和風險特徵。用於血液分離術的產品需要特殊的流量控制和高化學相容性。血液透析套裝則需要持久耐用和耐受頻繁操作，而輸血套裝則優先考慮易用性和嚴格的無菌性，以便快速床邊輸注。材料選擇進一步細分了產品線。聚氯乙烯(PVC) 因其柔軟性和熟悉的製造特性而仍然很常見，但熱可塑性橡膠(TPE) 為減少塑化劑用量和提高生物相容性提供了機會，從而影響臨床接受度和法規核准進程。

這項詳細的區域分析考察了美洲、歐洲、中東和非洲以及亞太地區的監管複雜性、採購結構和醫療保健服務體系的演變有何不同。

區域趨勢導致各主要地區在監管預期、採購行為和供應韌性方面有顯著差異。在美洲，嚴格的監管合規和完善的機構採購框架備受重視，推動了對檢驗的產品和全面的供應商服務模式的需求。分銷網路普遍成熟，主要面向醫院系統和大規模透析服務提供者。在歐洲、中東和非洲，報銷方案的多樣性和監管協調工作為尋求市場准入的製造商帶來了機會和挑戰，區域核准流程和各國特定的採購慣例影響著其市場部署策略。在亞太地區，醫療基礎設施的快速擴張和慢性病負擔的加重推動了對透析和輸血相關耗材的需求，但供應鏈的波動性和品質標準的差異性要求企業採取個人化的市場准入和宣傳策略。

競爭定位的策略性回顧：展示成熟製造商、利基創新者和契約製造製造商如何塑造其能力、供應彈性和臨床部署。

血液輸液管路市場的競爭動態呈現出多元化的態勢，既有成熟的醫療設備製造商，也有專業的零件供應商，還有專注於材料科學和連接性改進的小規模創新企業。大型製造商在監管申報、全球分銷基礎設施和服務水準保障方面擁有規模經濟優勢，能夠透過整合的供應合約和物流解決方案，為大規模醫院系統和透析網路提供服務。同時，專業供應商往往憑藉快速的產品改進、與特定領域的臨床夥伴關係建立合作關係以及差異化的材料技術（例如解決萃取、滅菌兼容性或人體工學操作方面的難題）來獲得市場支持。

為供應商和買家提供簡潔明了且切實可行的建議，以增強供應韌性、加速產品創新，並使採購與臨床安全目標保持一致。

行業領導者應優先考慮平衡短期業務永續營運和中期創新，以保持競爭力並支持臨床療效。首先，透過認證跨區域的多家製造商，並在合約中加入關稅、前置作業時間和品質補救措施等條款，來加強供應商組合。透過協作預測和風險分擔機制，加強與供應商的關係，以降低意外短缺的可能性，並實現從中斷中快速恢復。其次，投資於材料和設計方面的創新，以減少對有爭議的供應鏈投入的依賴，並提高在醫院和居家照護環境中的易用性。此類投資將有助於降低整體醫療保健成本，並提高臨床醫生的滿意度。

對用於產生可操作的臨床和採購見解的多方法研究過程、資料檢驗技術和專家參與方法進行透明的解釋。

本研究採用結構化、多面向的方法，以確保研究結果的可靠性、檢驗以及對決策者的意義。主要資料收集包括對臨床負責人、採購專家和生產品質專家的訪談，以了解實際營運、醫療設備相容性挑戰以及供應鏈優先事項。次要研究則利用監管出版刊物、標準文件和同行評審文獻，以當前安全性和性能預期為分析基礎。必要時，也會交叉引用產品規格和技術白皮書，檢驗有關材料、滅菌相容性和儀器介面的說法。

一份權威總結，重點闡述了在不斷變化的環境中，為確保臨床連續性、產品安全性和採購韌性所需的策略重點和協作努力。

總之，血液輸液管路領域正處於一個轉折點，材料創新、監管趨嚴性以及供應鏈的靈活性將決定哪些公司能夠成功滿足不斷變化的臨床需求。醫療服務提供者和供應商必須權衡各種相互衝突的挑戰：最大限度地減少污染和臨床風險，持續控制耗材成本，並在貿易和物流不確定性中維持供應的連續性。那些能夠整合卓越產品設計、靈活採購和數位化可追溯性的企業，將更有能力支援不斷擴展的醫療模式，例如家庭護理和高通量透析環境。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：採血管市場：依類型分類

  • 血漿分離套裝
  • 血液透析套裝
  • 輸血包

第9章：採血管市場：依材料分類

  • 聚氯乙烯
  • 熱可塑性橡膠

第10章：採血管市場：依最終用戶分類

  • 診所
  • 透析中心
  • 居家醫療
  • 醫院

第11章：按應用分類的血液試管市場

  • 可重複使用的
  • 一次性的

第12章：採血管市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：血液試管套裝市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：血管套裝市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國血液試管市場

第16章：中國血管套裝市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Angiplast Private Limited
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc
  • Becton Dickinson and Company
  • Cardinal Health
  • Danaher Corporation
  • Fresenius Kabi AG
  • GE HealthCare Technologies Inc
  • Gerresheimer AG
  • Haemonetics Corporation
  • Hemant Surgical Industries Ltd
  • ICU Medical Inc
  • JMS Co., Ltd.
  • Medtronic Plc
  • Merit Medical Systems Inc
  • Nipro Corporation
  • NxStage Medical
  • Shandong Weigao Group Medical Polymer
  • Smith & Nephew PLC
  • Smiths Medical
  • Terumo Corporation
  • Thermo Fisher Scientific
  • Vyaire Medical
Product Code: MRR-3204321AFA43

The Blood Tubing Set Market was valued at USD 1.04 billion in 2025 and is projected to grow to USD 1.12 billion in 2026, with a CAGR of 7.31%, reaching USD 1.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.04 billion
Estimated Year [2026] USD 1.12 billion
Forecast Year [2032] USD 1.71 billion
CAGR (%) 7.31%

A focused and practical introduction that contextualizes clinical, material, regulatory, and commercial dynamics shaping contemporary blood tubing set strategies

This executive summary introduces the complex and rapidly evolving blood tubing set landscape, framing the technical, regulatory, and commercial forces that are shaping procurement and clinical practice. Blood tubing sets operate at the intersection of medical device design, biocompatible materials science, and strict sterilization and safety protocols, which together determine clinical suitability and procurement preferences. The industry serves diverse clinical pathways including apheresis, hemodialysis, and blood transfusion, and each pathway imposes distinct requirements on set configuration, durability, and compatibility with ancillary equipment.

Throughout this summary, the aim is to synthesize recent developments into actionable context for decision-makers. Emphasis is placed on how material selection, single-use versus reusable paradigms, and channel dynamics influence adoption and supply resilience. Additionally, regulatory trajectories and reimbursement pressures are evaluated for their role in procurement decision-making and product innovation. By focusing on operational drivers and risk factors, readers will gain a clear sense of where investment, design refinement, and supply-chain attention should be prioritized to support patient safety and operational efficiency across clinical settings.

An exploration of the technological, regulatory, and operational inflection points that are redefining product design, safety, and supply integration across the sector

The landscape for blood tubing sets is undergoing transformative shifts driven by converging technological, regulatory, and operational pressures. Innovations in materials and extrusion processes are enabling slimmer profiles, enhanced kink resistance, and lower extractables, which in turn reduce adverse event risks and improve handling for clinicians. Meanwhile, sterility assurance methods and packaging innovations are reducing contamination risk while accommodating extended shelf-life needs in distributed care environments.

Operationally, the industry is moving toward modularity and compatibility as healthcare providers aim to standardize interfaces across devices to reduce training burden and inventory complexity. Concurrently, advances in remote monitoring and connected device ecosystems are encouraging integration of tubing sets with sensors that flag flow integrity or detect occlusions, thereby enabling earlier clinical intervention. Regulatory emphasis on post-market surveillance and traceability is accelerating adoption of unique device identifiers and serial tracking for critical consumables, prompting manufacturers to invest in supply-chain transparency and digital labeling. Taken together, these shifts are realigning priorities toward safety, interoperability, and data-enabled lifecycle management.

A comprehensive review of how recent tariff adjustments are reshaping procurement choices, manufacturing location strategies, and supplier diversification for critical consumables

Recent tariff actions have introduced new variables into procurement, cost management, and supply-chain strategy for organizations that rely on imported medical consumables. Tariff adjustments can create abrupt cost differentials between sourcing regions and prompt a re-evaluation of long-standing supplier relationships. Procurement teams may respond by diversifying supplier bases, increasing local inventory buffers, or accelerating qualification of alternative suppliers to mitigate exposure to changing duty structures.

Beyond immediate cost impacts, tariffs influence longer-term strategic decisions such as onshoring or nearshoring manufacturing, investing in automation to offset labor cost increases, and renegotiating contracts to include duty-inclusive pricing clauses. Clinical operations may encounter transitional friction as validated supply streams are adapted to new sources, requiring additional device compatibility testing and regulatory filings in some jurisdictions. Importantly, tariff-driven shifts also affect innovation pacing: manufacturers weighing capital investments may reassess timelines for facility expansion or tooling relocations in the context of evolving trade policy. As a result, both buyers and suppliers must maintain scenario-ready sourcing strategies and tighter collaboration to preserve continuity of care and control total cost of ownership.

Insightful segmentation-driven perspective explaining how type, material, end-user setting, channel, and single-use versus reusable dynamics materially affect procurement and design choices

Segment-level analysis reveals differentiated drivers and risk profiles across types, materials, end-user settings, sales channels, and usage models. Products designed for apheresis sets demand specialized flow control features and high chemical compatibility, whereas hemodialysis sets require sustained durability and resistance to frequent handling, and transfusion sets prioritize ease of use and strict sterility for rapid bedside administration. Material choices further stratify offerings: polyvinyl chloride remains common due to its flexibility and manufacturing familiarity, while thermoplastic elastomer presents opportunities for reduced plasticizer use and enhanced biocompatibility, influencing both clinical acceptance and regulatory review trajectories.

End-user environments impose distinct procurement and design imperatives. Clinics and dialysis centers often prioritize cost-efficiency and throughput, homecare settings emphasize simplified interfaces and caregiver-friendly designs, and hospitals require compatibility with a broad array of ancillary devices and adherence to institutional procurement standards. Sales channels shape access and service levels, with distributors and hospital pharmacies supporting bulk procurement and integrated logistics, online channels facilitating rapid replenishment for decentralized settings, and retail pharmacies offering patient-directed availability. Usage paradigms also bear on lifecycle decisions: reusable sets necessitate validated reprocessing protocols and capital investments in cleaning infrastructure, while single-use products simplify workflow and lower cross-contamination risk at the expense of recurring consumable spend. Synthesizing these segmentation dimensions highlights where manufacturers and purchasers should align product features, pricing models, and service offerings to match clinical workflows and regulatory expectations.

A nuanced regional analysis detailing how regulatory complexity, procurement structures, and healthcare delivery evolution differ across the Americas, Europe Middle East & Africa, and Asia-Pacific landscapes

Regional dynamics produce clear variations in regulatory expectations, purchasing behavior, and supply resiliency across major geographic groupings. In the Americas, a strong emphasis on rigorous regulatory compliance and established institutional procurement frameworks drives demand for validated products and comprehensive supplier service models, while distribution networks are typically mature and oriented toward hospital systems and large dialysis providers. In Europe, Middle East & Africa, heterogeneity in reimbursement systems and regulatory harmonization efforts creates both opportunities and complexity for manufacturers seeking market entry, with localized approval pathways and country-specific procurement practices shaping rollout strategies. In the Asia-Pacific region, rapid expansion of healthcare infrastructure and rising chronic disease burdens are increasing demand for dialysis and transfusion-related consumables, but supply-chain volatility and varying quality standards require tailored market access and education efforts.

Across all regions, geopolitical shifts and transport disruptions underscore the importance of regional manufacturing capacity and responsive logistics. Local clinical preferences and budget cycles further influence product design choices and inventory strategies, necessitating flexible pricing models and service commitments from suppliers. As healthcare delivery extends beyond hospitals into homecare and ambulatory settings globally, regional players must anticipate changing distribution patterns and adapt their commercialization tactics to maintain continuity of care while meeting diverse regulatory expectations.

A strategic review of competitive positioning showing how established manufacturers, niche innovators, and contract producers are shaping capability, supply resilience, and clinical adoption

Competitive dynamics in the blood tubing set domain reflect a blend of established medical device firms, specialized component manufacturers, and smaller innovators focused on material science or connectivity enhancements. Larger manufacturers bring scale advantages in regulatory submissions, global distribution infrastructures, and service-level guarantees, enabling them to serve major hospital systems and large dialysis networks with consolidated supply agreements and integrated logistics solutions. Conversely, specialized suppliers often gain traction through rapid product iteration, niche clinical partnerships, and differentiated material technology that addresses extractables, sterilization compatibility, or handling ergonomics.

Partnerships between OEMs and device integrators are increasingly common as manufacturers aim to ensure compatibility across therapeutic platforms and to embed traceability features into consumables. Contract manufacturing organizations and regional producers play a pivotal role in mitigating supply risk and enabling localized certifications, which can accelerate access to markets with stringent import regimes. Investors and corporate development teams are showing interest in firms that blend advanced materials expertise with scalable manufacturing processes, as these combinations can speed regulatory acceptance and lower lifecycle costs for providers. Overall, success favors organizations that combine rigorous quality systems, responsive customer support, and iterative product development aligned to evolving clinical workflows.

A concise set of pragmatic recommendations for suppliers and buyers to enhance supply resilience, accelerate product innovation, and align procurement with clinical safety objectives

Industry leaders should prioritize actions that balance immediate operational resilience with medium-term innovation to remain competitive and to support clinical outcomes. First, fortify supplier portfolios by qualifying multiple manufacturers across regions and by incorporating contractual terms that address tariffs, lead times, and quality recourse. Strengthening supplier relationships through collaborative forecasting and shared risk mechanisms will reduce the likelihood of unexpected shortages and enable faster recovery from disruptions. Second, invest in material and design innovation that reduces dependence on contentious supply-chain inputs and that enhances ease of use for bedside and homecare settings; such investments can yield lower total cost of care and improved clinician satisfaction.

Third, develop a clear reprocessing and single-use strategy that aligns clinical safety priorities with lifecycle economics; when pursuing reusable options, ensure validated cleaning protocols and staff training are in place. Fourth, embrace digital traceability and product identification systems to satisfy regulatory expectations, simplify recalls, and support inventory analytics; integrating traceability into procurement platforms will improve visibility across the lifecycle. Finally, build cross-functional governance teams that include clinical, procurement, regulatory, and quality stakeholders to accelerate supplier qualification and to ensure that product choices are evidence-driven and operationally feasible. Taken together, these measures will enhance supply continuity, enable cost control, and support safer patient care.

A transparent description of the multi-method research process, data validation techniques, and expert engagement approach used to produce actionable clinical and procurement insights

This research employed a structured, multi-method approach to ensure findings are robust, verifiable, and relevant to decision-makers. Primary evidence collection included interviews with clinical leaders, procurement specialists, and manufacturing quality experts to capture operational realities, device compatibility challenges, and supply-chain priorities. Secondary research drew on regulatory publications, standards documents, and peer-reviewed literature to ground analysis in current safety and performance expectations. Where applicable, product specifications and technical whitepapers were cross-referenced to validate claims about materials, sterilization compatibility, and device interfaces.

Analytical methods combined qualitative synthesis with scenario analysis to evaluate the implications of trade policy changes and regional supply constraints. Validation steps included triangulation across independent expert inputs and cross-checking of technical assertions against publicly available regulatory guidance. Throughout the process, attention was paid to excluding speculative financial metrics and instead emphasizing actionable operational, clinical, and strategic insights to inform procurement, product development, and policy decisions. Limitations are acknowledged where regional data granularity varies or where rapid policy changes necessitate ongoing monitoring to maintain relevance.

A definitive wrap-up highlighting the strategic priorities and coordinated actions required to secure clinical continuity, product safety, and procurement resilience in the evolving landscape

In conclusion, the blood tubing set landscape is at an inflection point where material innovation, regulatory rigor, and supply-chain agility will determine who succeeds in meeting evolving clinical needs. Providers and suppliers must reconcile competing imperatives: minimizing contamination and clinical risk, controlling recurring consumable costs, and maintaining supply continuity in the face of trade and logistics uncertainty. Organizations that integrate product design excellence with flexible sourcing and digital traceability will be best positioned to support expanding care models, including home-based therapies and high-throughput dialysis settings.

The path forward requires coordinated action across clinical, procurement, and manufacturing stakeholders to ensure product compatibility, validated reprocessing where applicable, and robust contingency planning. By aligning technical development with real-world clinical workflows and by investing in supplier diversification and traceability, stakeholders can improve patient safety while containing lifecycle costs. Continued monitoring of regulatory guidance, materials science advances, and trade policy developments will be essential to adapt strategies and sustain operational continuity as care delivery models evolve.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Tubing Set Market, by Type

  • 8.1. Apheresis Sets
  • 8.2. Hemodialysis Sets
  • 8.3. Transfusion Sets

9. Blood Tubing Set Market, by Material

  • 9.1. Polyvinyl Chloride
  • 9.2. Thermoplastic Elastomer

10. Blood Tubing Set Market, by End-User

  • 10.1. Clinics
  • 10.2. Dialysis Centers
  • 10.3. Homecare
  • 10.4. Hospitals

11. Blood Tubing Set Market, by Usage

  • 11.1. Reusable
  • 11.2. Single-Use

12. Blood Tubing Set Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Blood Tubing Set Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Blood Tubing Set Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Blood Tubing Set Market

16. China Blood Tubing Set Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Angiplast Private Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. B. Braun Melsungen AG
  • 17.9. Baxter International Inc
  • 17.10. Becton Dickinson and Company
  • 17.11. Cardinal Health
  • 17.12. Danaher Corporation
  • 17.13. Fresenius Kabi AG
  • 17.14. GE HealthCare Technologies Inc
  • 17.15. Gerresheimer AG
  • 17.16. Haemonetics Corporation
  • 17.17. Hemant Surgical Industries Ltd
  • 17.18. ICU Medical Inc
  • 17.19. JMS Co., Ltd.
  • 17.20. Medtronic Plc
  • 17.21. Merit Medical Systems Inc
  • 17.22. Nipro Corporation
  • 17.23. NxStage Medical
  • 17.24. Shandong Weigao Group Medical Polymer
  • 17.25. Smith & Nephew PLC
  • 17.26. Smiths Medical
  • 17.27. Terumo Corporation
  • 17.28. Thermo Fisher Scientific
  • 17.29. Vyaire Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD TUBING SET MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD TUBING SET MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD TUBING SET MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD TUBING SET MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD TUBING SET MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD TUBING SET MARKET SIZE, BY APHERESIS SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HEMODIALYSIS SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD TUBING SET MARKET SIZE, BY TRANSFUSION SETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD TUBING SET MARKET SIZE, BY POLYVINYL CHLORIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD TUBING SET MARKET SIZE, BY THERMOPLASTIC ELASTOMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD TUBING SET MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD TUBING SET MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD TUBING SET MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD TUBING SET MARKET SIZE, BY SINGLE-USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD TUBING SET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS BLOOD TUBING SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD TUBING SET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 86. GCC BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 90. GCC BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 101. G7 BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. G7 BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. NATO BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD TUBING SET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA BLOOD TUBING SET MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA BLOOD TUBING SET MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA BLOOD TUBING SET MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA BLOOD TUBING SET MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA BLOOD TUBING SET MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)